PreludeDx Unveils AidaBreast™: A Groundbreaking Multi-Omic Test for Early-Stage Breast Cancer PreludeDx has announced the publication of its innovative AidaBreast™ test, a multi-omic approach to predict breast cancer recurrence and therapy benefits.

PreludeDx Unveils AidaBreast™: A Groundbreaking Multi-Omic Test for Early-Stage Breast Cancer #United_States #Breast_Cancer #PreludeDx #Laguna_Hills #AidaBreast

PreludeDx Welcomes MiMi Reyes as Senior VP to Enhance Operational Strategies PreludeDx has appointed MiMi Reyes as Senior VP of Operations, aiming to bolster growth and improve laboratory capabilities in the face of rising demand.

PreludeDx Welcomes MiMi Reyes as Senior VP to Enhance Operational Strategies #USA #Breast_Cancer #PreludeDx #Laguna_Hills #MiMi_Reyes

PreludeDx Unveils Groundbreaking Validation for AidaBreast™ Multi-Omic Test in Breast Cancer Recurrence Prediction PreludeDx introduces AidaBreast™, the first validated multi-omic test predicting locoregional recurrence risk and radiation therapy benefits, transforming breast cancer treatment.

PreludeDx Unveils Groundbreaking Validation for AidaBreast™ Multi-Omic Test in Breast Cancer Recurrence Prediction #USA #Breast_Cancer #PreludeDx #Laguna_Hills #AidaBreast

PreludeDx's Breakthrough Study Reveals DCISionRT® Enhances DCIS Treatment Decisions PreludeDx has unveiled new data showing that the DCISionRT® test outperforms traditional factors in assessing treatment for DCIS, guiding more effective patient care.

PreludeDx's Breakthrough Study Reveals DCISionRT® Enhances DCIS Treatment Decisions #Breast_Cancer #DCISionRT #PreludeDx

How Hannah Storm's Journey with DCIS and PreludeDx Amplifies Breast Cancer Awareness Hannah Storm teams up with PreludeDx, leveraging her story as a DCIS patient advocate to empower women through informed cancer treatment decisions.

How Hannah Storm's Journey with DCIS and PreludeDx Amplifies Breast Cancer Awareness #United_States #DCISionRT #PreludeDx #Laguna_Hills #Hannah_Storm

PreludeDx Secures FDA Breakthrough Device Status for DCISionRT® Test in Breast Cancer Management PreludeDx has announced that their DCISionRT® test for detecting the benefits of radiation therapy in DCIS breast cancer patients has received FDA Breakthrough Device designation, marking a significant advancement in patient care.

PreludeDx Secures FDA Breakthrough Device Status for DCISionRT® Test in Breast Cancer Management #United_States #FDA_Approval #DCISionRT #PreludeDx #Laguna_Hills